EU Speedy Review Request For J&J’s Esketamine

 
• By Maureen Kenny

J&J is hoping its experimental new drug for treatment-resistant depression will join the select group of products benefitting from speedy review in the EU.

Fast Track
EMA's accelerated assessment mechanism allows drug reviews within 150 days • Source: Shutterstock

More from Review Pathways

More from Pathways & Standards